Trial Profile
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2023
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms HOVON134MF
- 15 Jun 2023 Results assessing the effect of pre-transplant pacritinib on the outcomes of Allogeneic stem cell transplantation with uniform conditioning regimen in Myelofibrosis, presented at the 28th Congress of the European Haematology Association.
- 19 Aug 2022 Planned End Date changed from 1 Mar 2023 to 1 Feb 2027.
- 19 Aug 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Jul 2023.